Preliminary trials demonstrate that Retatrutide – a dual agonist of gut hormone and glucose-dependent insulinotropic polypeptide receptors – presents a substantial advance in weight loss therapies. Unlike existing treatments , the peptide seems to influence hunger and calorie burn through separate routes. Although additional analysis is needed … Read More